Evaluation of the Difference between Cirrhotic Patients Receiving Propranolol and Those Receiving Propranolol Plus Losartan in terms of Renal Artery Resistive Index

Document Type : Original Article

Authors

1 Department of Internal Diseases, Mehr Hospital, Mashhad, Iran.

2 Department of Radiology, Zahedan University of Medical Sciences, Zahedan, Iran.

3 Assistant Professor of Gastroenterology and Hepatology, Zahedan Medical University, Zahedan, Iran.

4 Department of Heart Disease, Mehr Hospital, Mashhad, Iran.

Abstract

Introduction:
Portal hypertension is one of the main clinical complications of chronic liver diseases. In only 30% of cirrhotic patients who take propranolol, the hepatic venous pressure reduces to under 12 mm/Hg. The results of studies on the efficiency of losartan (an angiotensin II receptor antagonist) in reducing portal hypertension have been controversial so far. Hepatic venous pressure gradient (HVPG) is measured using an invasive method of catheterization. Studies have shown that the measurement of the renal resistive index (RI) by Doppler ultrasonography has a direct relationship with HVPG. The study population included cirrhotic patients who referred to Ali-ibn-Abi Talbe Clinic, Zahedan, Iran. This clinical trial was conducted based on a self-controlled method.
Materials and Methods:
In total, 30 cirrhotic patients who met the inclusion criteria were selected for the study.  The patients were treated with propranolol 10 mg twice a day for one month, and losartan was then added to their medication regimen. The renal RI of patients was measured before and after losartan administration.
Results:
The mean of renal RI of patients treated with both propranolol and losartan (0.659±0.58) was higher than that of the patients treated with only propranolol (0.635±0.597) (P=0.005).
Conclusion:
Our results showed that cirrhotic patients who received propranolol had high renal RI before and after receiving losartan. Accordingly, it seems that losartan had no effects on reducing HVPG hypertension in patients taking propranolol.

Keywords

References

1. Heebøll S, Villadsen GE, Aagaard NK, Grønbæk H, Vilstrup H, Keiding S. Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience. Scand J Gastroenterol. 2013 Aug;48(8):969-73. doi: 10. 3109/00365521.2013.805811. .
2. Castaño G, Viudez P, Riccitelli M, Sookoian S. A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients. Ann Hepatol. 2003 Jan-Mar; 2(1):36-40.
3. De BK, Bandyopadhyay K, Das TK, Das D, Biswas PK, Majumdar D, Mandal SK, Ray S, Dasgupta S. Portal pressure response to losartan compared with propranolol in patients with cirrhosis. Am J Gastroenterol. 2003 Jun; 98(6): 1371-6. doi: 10.1111/j.1572-0241. 2003. 07497.x.
4. González-Abraldes J, Albillos A, Bañares R, Del Arbol LR, Moitinho E, Rodríguez C, González M, Escorsell A, García-Pagán JC, Bosch J. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology. 2001 Aug;121(2): 382-8. doi: 10.1053/gast.2001.26288.
5. Groszmann Rj,Bosch J,Grace ND,Conn HO, Garcia-Tsao G,Navasa M,Albert J.etal. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage.Gasteroentrology1990 Nov ;99(5): 1401-7.doi:10.1016/0016-5085(90)91168-6.
6. García-Pagán JC, Escorsell A, Moitinho E, Bosch J. Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension. Semin Liver Dis. 1999; 19(4):427-38. doi: 10.1055/s-2007-1007130.
7. Feu F, García-Pagán JC, Bosch J, Luca A, Terés J, Escorsell A, Rodés J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet. 1995 Oct 21;346(8982): 1056-9. doi: 10.1016/s0140-6736(95)91740-3
8. Zhang F, Xu H, Chen M, Zhang M, Xiao J, Wang Y, He Q, Zhang W, Yin X, Zou X, Zhuge Y. Dose-dependent effect of propranolol on the hemodynamic response in cirrhotic patients with gastroesophageal varices. Eur J Gastroenterol Hepatol. 2019 Mar;31(3):368-374. doi: 10.1097/ MEG.0000000000001293
9. Arroyo V, Bosch J, Mauri M, Ribera F, Navarro-López F, Rodés J. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest. 1981 Jun; 11(3): 221-9. doi: 10.1111/j.1365-2362.1981. tb01844.x.
10. Chiang HT, Cheng JS, Lin M, Tseng WS, Chang JM, Lai KH. Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis. J Gastroenterol Hepatol. 1995 May-Jun; 10(3):256-60. doi: 10.1111/j.1440-1746. 1995. tb01090.x. 
11. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology. 1999 Feb; 29(2):334-9. doi: 10.1002/hep.510290203..
12. Castaño G, Viudez P, Sookoian S, Carlevaro O, Riccitelli M, Frider B. Propranolol y 5-mononitrato de isosorbide en pacientes con cirrosis: episodios hemodinámicos sistémicos y portales [Propranolol and 5-isosorbide mononitrate in patients with cirrhosis: systemic and portal hemodynamic events]. Gastroenterol Hepatol. 2000 Jun-Jul;23(6):275-81.
13. Berzigotti A, Casadei A, Magalotti D, Castaldini N, Losinno F, Rossi C, Zoli M. Renovascular impedance correlates with portal pressure in patients with liver cirrhosis. Radiology. 2006 Aug;240(2):581-6. doi: 10. 1148/ radiol.2401050585. Epub 2006 Jun 26.
14. Jeong PH, Baik SK, Choi YJ, Park DH, Kim MY, Kim HS, Lee DK, Kwon SO, Kim YJ, Park JW, Kim ND. [Comparison of Doppler ultrasonography and hepatic venous pressure gradient in assessing portal hypertension in liver cirrhosis]. Taehan Kan Hakhoe Chi. 2002 Sep;8(3):264-70..
15. Choi YJ, Baik SK, Park DH, Kim MY, Kim HS, Lee DK, Kwon SO, Kim YJ, Park JW. Comparison of Doppler ultrasonography and the hepatic venous pressure gradient in assessing portal hypertension in liver cirrhosis. J Gastroenterol Hepatol. 2003 Apr;18(4):424-9. doi: 10.1046/j. 1440-1746. 2003.02992.x.
16. Aydogdu S, Akil I, Akil T, Kabasakal C, Killi R, Mir S, Yagci R. Renal resistive indexes and some renal functions in liver cirrhotic children. Pediatr Int. 2004 Feb;46(1):67-71. doi: 10.1111/j.1442-200X.2004.01826.x. .
17. Sinkala E, Vinikoor M, Zyambo K, Besa E, Nsokolo B, Kelly P. Propranolol Reduces Portal Vein Diameter in Schistosomal Liver Disease with Portal Hypertension: A Prospective Cohort Study. Am J Trop Med Hyg. 2020 Apr;102(4):832-837. doi: 10.4269/ajtmh.19-0452.
18. Agasti AK, Mahajan AU, Phadke AY, Nathani PJ, Sawant P. Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease. J Dig Dis. 2013 May;14(5): 266-71. doi: 10.1111/1751-2980.12025.
19. De BK, Bandyopadhyay K, Das TK, Das D, Biswas PK, Majumdar D, Mandal SK, Ray S, Dasgupta S. Portal pressure response to losartan compared with propranolol in patients with cirrhosis. Am J Gastroenterol. 2003 Jun;98(6): 1371-6. doi:10.1111/j.1572-0241.2003.07497. x.
20. Yao H, Zhang C. Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials. Ir J Med Sci. 2018 Nov; 187(4): 925-934. doi: 10.1007/s11845-018-1765- 6.
21. Kim JH, Kim JM, Cho YZ, Na JH, Kim HS, Kim HA, Kang HW, Baik SK, Kwon SO, Cha SH, Kim YJ, Kim MY. Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension. Clin Mol Hepatol. 2014 Dec;20(4):376-83. doi: 10.3350/cmh.2014.20.4.376. .
22. Töx U, Steffen HM. Impact of inhibitors of the Renin-Angiotensin-aldosterone system on liver fibrosis and portal hypertension. Curr Med Chem. 2006; 13(30):3649-61. doi: 10.2174/ 09298670 6779026138.
23. Tandon P,  Abraldes JG,   Berzigotti A,   Garcia-
 
Pagan JC, Bosch J. Renin-angiotensin-aldosterone
inhibitors in the reduction of portal pressure: a
systematic review and meta-analysis. J Hepatol. 2010 Aug;53(2):273-82. doi: 10.1016/j. jhep. 2010.03.013.
24. Hennenberg M, Trebicka J, Biecker E, Schepke M, Sauerbruch T, Heller J. Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins. Hepatology. 2007 Feb;45(2):495-506. doi: 10. 1002/ hep.21502.
25. Chandana B Herath, Josephine A Grace, and Peter W Angus. Therapeutic potential of targeting the renin angiotensin system in portal hypertension World J Gastrointest Pathophysiol. 2013 Feb 15;4(1):1–11.doi:10. 4291/ wjgp. v4. i1.1.
26. Shim KY, Eom YW, Kim MY, Kang SH, Baik SK. Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension. Korean J Intern Med. 2018 May;33(3):453-461. doi: 10.3904/ kjim. 2017.317.
27. Yao H, Zhang C. Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials. Ir J Med Sci. 2018 Nov; 187(4): 925-934. doi: 10.1007/s11845-018-1765-6.
28. Jianrong Wang, Wenxia Lu, Jingjing Li, Rong Zhang, Yuqing Zhou, Qin Yin,Yuanyuan Zheng, Fan Wang, Yujing Xia,Kan Chen,Sainan Li, Tong Liu, Jie Lu,Yingqun Zhou,and  Chuan-Yong Guo.Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta-analysis. Exp Ther Med.2017 May;13(5):1977-1985.doi: 10. 3892/ etm.2017.4210
Journal of Patient Safety & Quality Improvement
Volume 9, Issue 2
April 2021
Pages 91-97

Files

Share

How to cite

Statistics